Dr. Andrea Barthwell, Chief Medical Officer
Andrea Grubb Barthwell, M.D., D.F.A.S.A.M. is the Chief Medical Officer for Treatment Management Company. Dr. Barthwell leads, educates and guides the treatment of patients through evidence-based, clinical best practices in each of 31 licensed, facility locations across the nation. She is also the founder and CEO of Two Dreams, a comprehensive wellness center for the treatment of alcoholism and substance use disorders and the founder and Chief Executive Officer of the Washington, DC-based global healthcare and policy-consulting firm EMGlobal LLC.
Dr. Barthwell served as Deputy Director for Demand Reduction in the Office of National Drug Control Policy (ONDCP) under President George W. Bush from 2002 to 2004. As a member of the President’s sub-cabinet, Dr. Barthwell was a principal advisor on policies aimed at reducing the demand for illicit drugs across the continuum of prevention intervention.
Dr. Barthwell’s current work is focused on developing strategies to expand access to treatment for opioid dependence disorder, expanding practitioner knowledge of urine drug testing in the identification and treatment of substance use disorders, and helping individuals and families prevent substance use disorders with the lecture series, “The Parents Academy.”
Dr. Barthwell received a Bachelor of Arts degree in Psychology from Wesleyan University and a Doctorate of Medicine from the University of Michigan Medical School. Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area. She was a founding member of the Chicago Area AIDS Task Force, hosted a weekly local cable show on AIDS, and was president of the American Society of Addiction Medicine (ASAM).
In 2003, Dr. Barthwell received the Betty Ford Award from the Association for Medical Education and Research in Substance Abuse. In 1997, Dr. Barthwell’s peers named her one of the “Best Doctors in America” in addiction medicine.
Dr. Barthwell is widely published and has served on a number of national advisory boards and committees, most notably the National Institute on Drug Abuse (NIDA), the Center for Substance Abuse Treatment (CSAT), and the US Food and Drug Association (FDA) Drug Abuse Advisory Committee.